biote Corp. (BTMD) Stock Forecast
Data as of Aug 7, 2026Healthcare · Current price $1.63 (-0.31%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
BTMD vs Sector & Market
| Metric | BTMD | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.33 | 2.25 | 2.42 |
| Analyst Count | 3 | 8 | 18 |
| Target Upside | +44.1% | +16316.1% | +17.2% |
| P/E Ratio | 2.55 | 3.41 | 35.26 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $192M | $192M | $193M | 4 |
| 2027-12-31 | $205M | $205M | $205M | 3 |
| 2028-12-31 | $219M | $220M | $221M | 1 |
| 2029-12-31 | $233M | $234M | $236M | 1 |
| 2030-12-31 | $246M | $247M | $249M | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $0.16 | $0.29 | $0.43 | 2 |
| 2027-12-31 | $0.35 | $0.36 | $0.36 | 1 |
| 2028-12-31 | $0.62 | $0.62 | $0.63 | 1 |
| 2029-12-31 | $0.66 | $0.66 | $0.67 | 1 |
| 2030-12-31 | $0.70 | $0.70 | $0.71 | 1 |
Frequently Asked Questions
What is the analyst consensus for BTMD?
The consensus among 3 analysts covering biote Corp. (BTMD) is Buy with an average price target of $3.25.
What is the highest price target for BTMD?
The highest analyst price target for BTMD is $4.00.
What is the lowest price target for BTMD?
The lowest analyst price target for BTMD is $2.50.
How many analysts cover BTMD?
3 analysts have issued ratings for biote Corp. in the past 12 months.
Is BTMD a buy or sell right now?
Based on 3 analyst ratings, BTMD has a consensus rating of Buy (2.33/5) with a +44.1% upside to the consensus target of $3.25.
What are the earnings estimates for BTMD?
Analysts estimate BTMD will report EPS of $0.29 for the period ending 2026-12-31, with revenue estimated at $192M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.